China SXT Pharmaceuticals (2RY3) Income Statement
China SXT Pharmaceuticals Income Statement
Last quarter (Q4 2026), China SXT Pharmaceuticals's total revenue was $1.20M, an increase of 162.99% from the same quarter last year. In Q4, China SXT Pharmaceuticals's net income was $163.72K. See China SXT Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| $ 1.07M | $ 1.74M | $ 1.93M | $ 1.97M | $ 2.60M | |
| $ 183.28K | $ 367.43K | $ 553.97K | $ 426.27K | $ 1.25M | |
| $ 7.31M | $ 3.05M | $ 3.07M | $ 6.03M | $ 6.44M | |
| Depreciation and Amortization | $ 143.22K | $ 82.30K | $ 203.25K | $ 250.16K | $ 320.01K |
| $ -6.98M | $ -2.57M | $ -2.35M | $ -5.21M | $ -5.05M | |
| $ -7.12M | $ -2.68M | $ -2.52M | $ -5.61M | $ -5.19M | |
| $ 1.05M | $ -623.17K | $ -583.32K | $ -327.26K | $ -218.28K | |
| $ -6.07M | $ -3.30M | $ -3.10M | $ -5.93M | $ -5.41M | |
| $ -6.21M | $ -3.30M | $ -3.10M | $ -5.93M | $ -5.74M | |
| Per Share Metrics | |||||
| Basic EPS | $ -913.00 | $ -818.00 | $ -357.00 | $ -2223.00 | $ -13792.00 |
| Diluted EPS | $ -913.00 | $ -818.00 | $ -357.00 | $ -2223.00 | $ -13792.00 |
| Weighted Average Shares Outstanding | 6.80K | 4.04K | 8.67K | 2.67K | 416 |
| Weighted Average Shares Outstanding (Diluted) | 6.80K | 4.04K | 8.67K | 2.67K | 416 |
Currency in USD
